ArticlePloS one2010
Isolation, characterization, and stability of discretely-sized nanolipoprotein particles assembled with apolipophorin-III.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Foam fractionation of a recombinant biosurfactant apolipoprotein.Journal of biotechnology · 2022Article
- Reconstituted HDL as a therapeutic delivery device.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2021Review
- Nanolipoprotein particles for co-delivery of cystine-knot peptides and Fab-based therapeutics.Nanoscale advances · 2021Article
- Functionalized Particles Designed for Targeted Delivery.Polymers · 2021Review
- Cationic HDL mimetics enhance in vivo delivery of self-replicating mRNA.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Characterization ofFrontiers in immunology · 2020Article
- Lipid composition dictates serum stability of reconstituted high-density lipoproteins: implications for in vivo applications.Nanoscale · 2018Article
- Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system.PloS one · 2017Article
- Article
- Optimized phospholipid bilayer nanodiscs facilitate high-resolution structure determination of membrane proteins.Journal of the American Chemical Society · 2013Article
- Apolipoprotein-induced conversion of phosphatidylcholine bilayer vesicles into nanodisks.Biochimica et biophysica acta · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNanolipoprotein particles (NLPs) are discoidal, nanometer-sized particles comprised of self-assembled phospholipid membranes and apolipoproteins. NLPs assembled with human apolipoproteins have been used for myriad biotechnology applications, including membrane protein solubilization, drug delivery, and diagnostic imaging. To expand the repertoire of lipoproteins for these applications, insect apolipophorin-III (apoLp-III) was evaluated for the ability to form discretely-sized, homogeneous, and stable NLPs. METHODOLOGY: Four NLP populations distinct with regards to particle diameters (ranging in size from 10 nm to >25 nm) and lipid-to-apoLp-III ratios were readily isolated to high purity by size exclusion chromatography. Remodeling of the purified NLP species over time at 4 degrees C was monitored by native gel electrophoresis, size exclusion chromatography, and atomic force microscopy. Purified 20 nm NLPs displayed no remodeling and remained stable for over 1 year. Purified NLPs with 10 nm and 15 nm diameters ultimately remodeled into 20 nm NLPs over a period of months. Intra-particle chemical cross-linking of apoLp-III stabilized NLPs of all sizes.
conclusionsApoLp-III-based NLPs can be readily prepared, purified, characterized, and stabilized, suggesting their utility for biotechnological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.